Stakeholders refer to organizations or individuals affected by the Company's operations, products, or services. The Company should identify stakeholders and respond to their reasonable expectations and interests. The Company's stakeholders include shareholders (investors), employees, clients, drug development partners, suppliers, groups, and competent authorities. We strive to maintain positive relations with stakeholders and communicate issues with internal and external parties, include stakeholders’ issues of concern in relevant units’ responsibilities and work plans, respond to changes in environmental trends and amendments to laws and regulations in conjunction with relevant units. To meet stakeholders’ expectations, the Company adopts various communication methods to ensure that relevant tasks are completed and maintains smooth communication channels as well. The management team regularly adopts relevant feedback as a reference for future improvement or plans.
In the corporate sustainable development, we need to constantly communicate with stakeholders to understand their needs as a reference for the formulation of company policies and plans. During the implementation of policies and plans, we should also pay attention to stakeholders’ feedback all the times for subsequent improvement.
The Corporate Governance Officer reports the communications with stakeholders to the Board of Directors annually. The communications with stakeholders including feedbacks from stakeholders, responses and follow-up response plans have been reported to the Board of Directors on Aug. 3, 2023 and Dec. 14, 2023.
Stakeholders | Main party | Issues of concern | Responses | Communication Performance in 2023 |
---|---|---|---|---|
Shareholders (Investors) |
|
|
|
|
Employees | All Employees |
|
|
|
Partners |
|
|
|
|
Clients |
|
|
Relevant seminars and visits |
|
Suppliers |
|
|
|
|
Groups |
|
|
Communication between event organizers and social welfare groups |
|
Competent Authorities | Government |
|
|
|
Spokesperson: Ted Kao
Title: Chief Financial Officer
Phone: 02-2655-8525 #5154
Email: ted_kao@tshbiopharm.com
Deputy Spokesperson and Investor Relations Contact: Shuping Huang
Title: Manager of Administration Department
Phone: 02-2655-8525 #5105
Email: Shupinghuang@tshbiopharm.com
Email: ethical@tshbiopharm.com
Contact: Jessica Wu
Title: Chief Internal Auditor
Phone: 02-2655-8525 #5523
Email: Jessica_wu@tshbiopharm.com
Contact: Han Hsieh
Title: Director of Corporate Development and Research
Phone: 02-2655-8525 #5412
Email: han_hsieh@tshbiopharm.com
Contact: Eliza Chang
Title: Senior Specialist
Phone: 02-2655-8525 #5131
Email: eliza@tshbiopharm.com
Contact: Isa Wang
Title: Assistant Manager
Phone: 02-2655-8525 #5111
Email: isa_wang@tshbiopharm.com